Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia–reperfusion injury

补体系统 凝集素途径 促炎细胞因子 药理学 替代补体途径 补体膜攻击复合物 肾缺血 移植 炎症 肾 再灌注损伤 免疫学 医学 化学 缺血 内科学 免疫系统
作者
Anjan K. Bongoni,Bence Kiss,Jennifer L. McRae,Evelyn Salvaris,Nella Fisicaro,Fenella Muntz,Bálint Zoltán Németh,Zoltán Attila Nagy,Andrea Kocsis,Péter Gál,Peter J. Cowan,Gábor Pál
出处
期刊:Proceedings of the National Academy of Sciences of the United States of America [National Academy of Sciences]
卷期号:122 (16): e2424754122-e2424754122 被引量:4
标识
DOI:10.1073/pnas.2424754122
摘要

Renal ischemia-reperfusion injury (IRI) is a common complication in several clinical scenarios including kidney transplantation. Mannan-binding lectin-associated serine proteinase (MASP)-2 is essential for activation of the complement lectin pathway, which has been implicated in the pathogenesis of renal IRI and therefore represents a potential therapeutic target. We developed a new, affinity-enhanced MASP-2 inhibitor, EVO24, by directed evolution of the D2 domain of human tissue factor pathway inhibitor. EVO24 was fused with a human IgG1-Fc to create the homodimer EVO24L, which potently and selectively inhibited the lectin pathway in human and mouse serum in vitro. EVO24L was tested in a mouse model of unilateral warm renal IRI. EVO24L administered before and after ischemia significantly protected against IRI, with improved renal function as well as reduced tubular injury and inflammatory cell infiltration at 24 h compared to vehicle-treated mice. Immunofluorescence analyses showed reduced deposition of complement components (C3d, C4d, and C9) and reduced expression of VCAM-1, indicating a decrease in complement activation and endothelial cell activation. Additionally, EVO24L treatment lowered plasma levels of complement C5a, hyaluronan (a marker of endothelial glycocalyx shedding), and the proinflammatory cytokines IL-6 and TNF-α. Our findings indicate that EVO24L inhibits acute inflammatory responses in renal IRI by blocking the lectin pathway, confirming the important role of this pathway in acute ischemic kidney injury and warranting further investigation of EVO24L in clinical settings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1192237414发布了新的文献求助10
刚刚
1秒前
Rommel发布了新的文献求助10
1秒前
1秒前
Liusong完成签到,获得积分10
2秒前
无花果的应助被小茜采纳,获得10
2秒前
wly1121完成签到,获得积分10
2秒前
丘比特的应助被什么呀采纳,获得10
2秒前
小蘑菇的应助被凶狠的寒梅采纳,获得10
2秒前
临风不自傲完成签到,获得积分10
3秒前
liu完成签到,获得积分10
3秒前
慕青的应助被jingyi采纳,获得10
3秒前
3秒前
科研通AI6.4的应助被尊敬湘采纳,获得10
3秒前
今后的应助被张微采纳,获得10
3秒前
潘火柴人完成签到,获得积分10
4秒前
Maestro_S的应助被栀子采纳,获得10
4秒前
吉康医学发布了新的文献求助10
4秒前
爆米花的应助被研友_nVj3yn采纳,获得10
4秒前
松鼠叶发布了新的文献求助10
5秒前
斯文败类的应助被1192237414采纳,获得10
5秒前
5秒前
5秒前
CHA关闭了CHA的文献求助
6秒前
lkk完成签到,获得积分10
6秒前
kant发布了新的文献求助10
6秒前
7秒前
天天快乐的应助被春花奶采纳,获得10
7秒前
7秒前
chunjianghua完成签到,获得积分10
7秒前
以利沙发布了新的文献求助10
7秒前
8秒前
8秒前
随风发布了新的文献求助10
8秒前
犹豫安波发布了新的文献求助10
8秒前
李健的粉丝团团长的应助被hin采纳,获得10
9秒前
秋风的应助被谢耳朵采纳,获得10
9秒前
影川发布了新的文献求助50
9秒前
9秒前
Lumu271199的应助被yy采纳,获得50
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8155833
求助须知:如何正确求助?哪些是违规求助? 9552176
关于积分的说明 21708409
捐赠科研通 7745046
什么是DOI,文献DOI怎么找? 3426296
关于科研通互助平台的介绍 2551259
邀请新用户注册赠送积分活动 2469982